Strong Q1 sales for Novartis
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sales of swine flu vaccine helped the Swiss pharmaceutical group Novartis to sales of $2.95bn (£1.9bn) in the first quarter of 2010, the company announced yesterday. Total sales jumped by 25 per cent, to $12.1bn, sending the shares up by nearly 1.5 per cent on the Zurich stock exchange. Novartis said that it expects a strong performance this year from its pharmaceuticals division, after disclosing that drug sales were ahead of its own forecasts. "The strong sales and profit contributions in the first quarter of 2010 from fulfilment of agreed-upon government supply contracts for [H1N1] pandemic vaccines, with sales approximately $400m above the group's target at the beginning of the year, will further strengthen these prospects," Novartis said in a statement. The quarterly results were the first for the new chief executive, Joe Jimenez, and finance director, Jon Symonds.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments